CD70 and nasopharyngeal carcinoma: In conclusion, our multiomics-driven functional investigations provide pre-clinical insights into how Tregs are developed, activated, and sustained in the NPC microenvironment, and show that CD70 inhibition is a therapeutically feasible approach to overcome the immunosuppressive TME, synergistically enhancing the efficacy of anti-PD-1 treatment.